Group 1 - The core viewpoint is that Meinohua (603538.SH) is currently discussing the development of a hangover relief product as an alternative offering with its partners [1] Group 2 - The company is actively engaging with partners regarding the potential of the hangover relief product [1]

上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市浦东新区南泉北路 429 号泰康保险大厦 26 楼 | 邮政编码：200120 上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：宁波美诺华药业股份有限公司 宁波美诺华药业股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会于 2025 年 9 月 11 日在浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室召开。上海市广发律师事务所经公司聘请，委派姚培琪律师、 王俊峰律师出席现场会议。根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等法律法 规、其他规范性文件以及《宁波美诺华药业股份有限公司章程》（以下简称"《公 司章程》"）的规定，就本次股东大会的召集和召开程序、召集人及出席会议人 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-099 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 （二）股东大会召开的地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室。 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 357 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 60,389,820 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 27.3737 | | 份总数的比例（%） | | （四）表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长姚成志先生主持会议。会议采 ...

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Company Overview - Meinuohua, established on February 19, 2004, and listed on April 7, 2017, is located in Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of specialty raw materials (including intermediates) and finished pharmaceuticals [1][2]. Financial Performance - For the first half of 2025, Meinuohua achieved a revenue of 677 million yuan, representing a year-on-year growth of 11.42%. The net profit attributable to shareholders was 49.06 million yuan, showing a significant increase of 158.97% [2]. - Since its A-share listing, Meinuohua has distributed a total of 149 million yuan in dividends, with 50.58 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Meinuohua's stock price was 25.20 yuan per share, with a market capitalization of 5.54 billion yuan. The stock has increased by 99.05% year-to-date, but has seen a decline of 1.72% over the past five trading days and 12.10% over the past 20 days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) six times this year, with the most recent appearance on August 28, where it recorded a net buy of -113 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Meinuohua was 32,400, an increase of 17.14% from the previous period. The average number of circulating shares per shareholder was 6,590, a decrease of 14.63% [2]. - Notably, some institutional investors, including融通健康产业灵活配置混合A/B and 光大保德信信用添益债券A类, have exited the list of the top ten circulating shareholders [3]. Business Segments - The company's revenue composition includes 57.74% from intermediates and raw materials, 29.53% from formulations, 8.87% from CDMO (Contract Development and Manufacturing Organization), 3.52% from trade, and 0.34% from other sources [1]. Industry Classification - Meinuohua is classified under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sectors. It is associated with concepts such as assisted reproduction, hepatitis treatment, pet economy, raw materials, and small-cap stocks [2].

Group 1 - The company will hold a half-year performance briefing on September 16, 2025, from 09:30 to 11:30 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live stream and online interaction [3][4] - Investors can submit questions from September 9 to September 15, 2025, and the company will address common concerns during the briefing [2][4][3] Group 2 - Key participants in the briefing include the Chairman and General Manager, Yao Chengzhi, and the Secretary of the Board and Financial Officer, Ying Gaofeng [4] - Investors can access the briefing through the Shanghai Stock Exchange Roadshow Center website [4][6] - After the briefing, investors can review the main content and proceedings on the Roadshow Center website [6][7]

（文章来源：证券日报） 证券日报网讯 9月8日晚间，美诺华发布公告称，公司计划于2025年09月16日（星期二）09：30-11：30 举行2025年半年度业绩说明会。 ...

| | | 宁波美诺华药业股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 16 日 （星期二） 09:30-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 本次投资者说明会以视频结合网络互动召开，公司将针对 2025 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 09 月 16 日 （星期二） 09:30-11:30 （二）会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 三、 参加人员 董事长兼总经理：姚成志 董事会秘书兼财务负责人：应高峰 ...

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]